BRPI0712346B8 - processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica - Google Patents

processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica

Info

Publication number
BRPI0712346B8
BRPI0712346B8 BRPI0712346A BRPI0712346A BRPI0712346B8 BR PI0712346 B8 BRPI0712346 B8 BR PI0712346B8 BR PI0712346 A BRPI0712346 A BR PI0712346A BR PI0712346 A BRPI0712346 A BR PI0712346A BR PI0712346 B8 BRPI0712346 B8 BR PI0712346B8
Authority
BR
Brazil
Prior art keywords
tmc125
solid
pharmaceutical
solid dispersion
pharmaceutical formulation
Prior art date
Application number
BRPI0712346A
Other languages
English (en)
Inventor
Rene Irene Kiekens Filip
Firmin Marceline Voorspoels Jody
Elvire Colette Baert Lieven
Original Assignee
Janssen R & D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37179187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0712346(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R & D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R & D Ireland
Publication of BRPI0712346A2 publication Critical patent/BRPI0712346A2/pt
Publication of BRPI0712346B1 publication Critical patent/BRPI0712346B1/pt
Publication of BRPI0712346B8 publication Critical patent/BRPI0712346B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

processo para preparar formulações de tmc125 secas por atomização. a presente invenção refere-se a um processo para produzir um pó seco por atomização que compreende celulose microcristalina em uma dispersão sólida do composto anti-hiv etravirina (tcm125) em um polímero solúvel em água.
BRPI0712346A 2006-06-06 2007-06-06 processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica BRPI0712346B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06115029.8 2006-06-06
EP06115029 2006-06-06
PCT/EP2007/055607 WO2007141308A1 (en) 2006-06-06 2007-06-06 Process for preparing spray dried formulations of tmc125

Publications (3)

Publication Number Publication Date
BRPI0712346A2 BRPI0712346A2 (pt) 2012-07-17
BRPI0712346B1 BRPI0712346B1 (pt) 2020-09-29
BRPI0712346B8 true BRPI0712346B8 (pt) 2021-05-25

Family

ID=37179187

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712346A BRPI0712346B8 (pt) 2006-06-06 2007-06-06 processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica

Country Status (27)

Country Link
US (2) US20090197903A1 (pt)
EP (1) EP2029110B1 (pt)
JP (1) JP5089685B2 (pt)
KR (1) KR101179905B1 (pt)
CN (1) CN101453989B (pt)
AT (1) ATE522202T1 (pt)
AU (1) AU2007255418C1 (pt)
BR (1) BRPI0712346B8 (pt)
CA (1) CA2651665C (pt)
CY (1) CY1112154T1 (pt)
DK (1) DK2029110T3 (pt)
EC (1) ECSP088938A (pt)
ES (1) ES2372983T3 (pt)
HK (1) HK1129579A1 (pt)
HR (1) HRP20110883T1 (pt)
IL (1) IL195710A (pt)
ME (1) ME01305B (pt)
MX (1) MX2008015686A (pt)
NO (1) NO343652B1 (pt)
NZ (1) NZ572702A (pt)
PL (1) PL2029110T3 (pt)
PT (1) PT2029110E (pt)
RS (1) RS52053B (pt)
RU (1) RU2406502C2 (pt)
SI (1) SI2029110T1 (pt)
WO (1) WO2007141308A1 (pt)
ZA (1) ZA200810345B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
US9050326B2 (en) 2008-04-02 2015-06-09 Astellas Pharma Inc. Amido derivatives-contained pharmaceutical composition
WO2010006697A2 (en) * 2008-06-30 2010-01-21 Tibotec Pharmaceuticals Powders for reconstitution
US8703786B2 (en) * 2011-12-07 2014-04-22 Texas Southern University Etravirine formulations and uses thereof
EP2911651B1 (en) * 2012-09-27 2016-06-22 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
CN112105680A (zh) * 2018-05-11 2020-12-18 株式会社三养社 固体分散体、其制备方法、使用其的扩链聚氨酯和包含其的环氧树脂组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2920956B2 (ja) * 1989-10-06 1999-07-19 藤沢薬品工業株式会社 ニルバジピン含有持続性錠剤
US6395303B1 (en) 1996-06-10 2002-05-28 Edward Mendell Co., Inc. Process for preparing a directly compressible solid dosage form containing microcrystalline cellulose
JPH107558A (ja) * 1996-06-19 1998-01-13 Eisai Co Ltd 溶解性改善製剤
SK287270B6 (sk) 1998-11-10 2010-05-07 Janssen Pharmaceutica N. V. Derivát pyrimidínu
ATE400252T1 (de) * 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
DE19945982A1 (de) 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
NZ517025A (en) * 1999-09-24 2003-07-25 Janssen Pharmaceutica Nv Antiviral compositions
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
CN1787808A (zh) * 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
DE60311875T2 (de) * 2002-12-19 2007-08-30 Pharmacia Corp. Nicht-hygroskopische formulierung, die einen hygroskopischen wirkstoff enthält
CN1822843B (zh) * 2003-07-17 2010-04-28 泰博特克药品有限公司 制备含有抗病毒药物颗粒的方法
JP2007513937A (ja) * 2003-12-09 2007-05-31 ファイザー インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤を含む組成物

Also Published As

Publication number Publication date
KR20090024131A (ko) 2009-03-06
WO2007141308A1 (en) 2007-12-13
JP5089685B2 (ja) 2012-12-05
AU2007255418A1 (en) 2007-12-13
JP2009539804A (ja) 2009-11-19
IL195710A0 (en) 2009-09-01
SI2029110T1 (sl) 2012-01-31
ME01305B (me) 2012-04-30
US20120208834A1 (en) 2012-08-16
BRPI0712346B1 (pt) 2020-09-29
AU2007255418B2 (en) 2010-12-23
ES2372983T3 (es) 2012-01-30
PL2029110T3 (pl) 2012-03-30
US9603803B2 (en) 2017-03-28
HK1129579A1 (en) 2009-12-04
EP2029110B1 (en) 2011-08-31
NZ572702A (en) 2011-09-30
NO20090061L (no) 2009-01-06
AU2007255418C1 (en) 2011-08-18
CA2651665A1 (en) 2007-12-13
CN101453989B (zh) 2012-06-13
HRP20110883T1 (hr) 2012-01-31
ECSP088938A (es) 2009-01-30
RU2406502C2 (ru) 2010-12-20
PT2029110E (pt) 2011-11-23
CN101453989A (zh) 2009-06-10
CA2651665C (en) 2010-04-27
DK2029110T3 (da) 2011-12-19
ZA200810345B (en) 2012-05-30
US20090197903A1 (en) 2009-08-06
NO343652B1 (no) 2019-04-29
RS52053B (en) 2012-04-30
ATE522202T1 (de) 2011-09-15
EP2029110A1 (en) 2009-03-04
KR101179905B1 (ko) 2012-09-07
IL195710A (en) 2014-02-27
CY1112154T1 (el) 2015-12-09
RU2008152411A (ru) 2010-07-20
MX2008015686A (es) 2009-01-12
BRPI0712346A2 (pt) 2012-07-17

Similar Documents

Publication Publication Date Title
ECSP10010295A (es) Formulacion de anticuerpo
BRPI0712346B8 (pt) processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica
WO2010031720A3 (en) Novel antibody formulation
EP2155243B8 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
WO2007150030A3 (en) Microfluidic synthesis of organic nanoparticles
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
BRPI0610420A2 (pt) processo para a preparação de uma dispersão polimérica aquosa, dispersão polimérica aquosa, uso de uma dispersão polimércia aquosa, preparação de um pó polimérico, e, uso de um pó polimérico
WO2012009778A3 (en) A stable topical composition and a process for producing a stable topical composition
MY146557A (en) Revaprazan-containing solid dispersion and process for the preparation thereof
WO2008025015A3 (en) Epitope-protein scaffolds and their use
EA200702589A1 (ru) 2,6-хинолинильные производные, способы их получения и их применение
BRPI0607905A2 (pt) processo para preparar uma dispersão polimérica aquosa, dispersão polimérica aquosa, uso de uma dispersão polimérica aquosa, preparação de um pó de polímero, e, uso de um pó de polímero
WO2009002538A3 (en) Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2009094457A3 (en) Substituted benzhydrylethers
BRPI0516464B8 (pt) método para a preparação de um produto farmacêutico
WO2008073863A3 (en) Preparation and utility of substituted allylamines
WO2009010787A3 (en) Stable pharmaceutical compositions comprising one or more hmg-coa reductase inhibitors
WO2009028598A1 (ja) 徐放性製剤及びその製造方法
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
WO2011107866A3 (en) Silyl-derivatives of polysaccharides
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
BRPI0810315A2 (pt) "processo de fbricação de um produto celulósico, produto celulósico que pode ser obtido por meio do processo, dispersão e uso da dispersão".
WO2011127244A8 (en) ATAZANAVIR SULFATE FORMULATIONS WITH IMPROVED pH EFFECT
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2007042571A8 (en) Novel pyrimidine-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF